Evidence mapPaperPMID 37095062Full record

ArticleCancer reports (Hoboken, N.J.)2023

Global burden of female breast cancer and its association with socioeconomic development status, 1990-2044.

Jingya Zhang, Yongbo Lu, Ning Zhang, Zeru Yu, Haorao Li, Rongxin He, Ying Mao, Bin Zhu

Open access · goldAbstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Dual Role ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jingya ZhangSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.ORCID 0000-0002-2657-9802
Yongbo LuSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Ning ZhangSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Zeru YuSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Haorao LiSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Rongxin HeVanke School of Public Health, Tsinghua University, Beijing, China.
Ying MaoSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Bin ZhuSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Xi'an Jiaotong University · CNSouthern University of Science and Technology · CNVanke (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is a widespread disease in women worldwide.

aimWe aimed to explore the global epidemiological trends of female breast cancer (FBC) between 1990 and 2044. METHODS AND

resultsDisease burden, population, and socio-demographic index (SDI) data were obtained from the Global Health Data Exchange (GHDx) database. We analyzed temporal trends, age differences, risk factors, and geographic patterns of FBC disease burden globally and explored the association between age-standardized incidence rate (ASIR) of FBC and SDI. Bayesian age-period-cohort model was also performed to predict the changes in FBC incidence worldwide from 2020 to 2044. First, the global ASIR of FBC increased by 14.31% from 1990 to 2019 (95% Uncertainty Interval 4.75% to 23.98%). The death rate presented a falling trend. Second, alcohol use is the most-highlighted risk factor for FBC in some high-income regions such as Europe. A high fasting plasma glucose levels is the most prominent risk factor for FBC in Latin America and Africa. Third, the ASIR of the FBC increases with the SDI. Fourth, the incidence is expected to increase faster among women aged 35-60 years and fastest for those aged 50-54 years from 2020 to 2044. Countries with a high incidence of FBC that is expected to increase significantly include Barbados, Burkina Faso, Senegal, Monaco, Lebanon, Togo, and Uganda.

conclusionThe disease burden of FBC varies worldwide; the findings suggest attaching importance to the control of middle and low-middle SDI regions. Public health as well as cancer prevention experts should pay more attention to regions and populations at an increased risk of developing FBC, focusing on their prevention and rehabilitation while conducting further epidemiological studies to investigate the risk factors of their increase.

Indexed as

Breast NeoplasmsSocioeconomic FactorsAdolescentAdultAgedAged, 80 and overAge DistributionBayes TheoremDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansMiddle AgedRisk FactorsYoung Adultfemale breast cancerglobalincidencepredictionrisk factor

Identifiers

PMID37095062
PMCPMC10440843
OpenAlexW4366850698

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.